| Name | Paper | Description of Comparison | Gene | RSID | Association | Disease Status | MAF | Statistical Odds Ratio | Statistical P-value |
| Namkoong_rs1886814 | Japan COVID-19 Task Force: a nation-wide consortium to elucidate host genetics of COVID-19 pandemic in Japan | COVID-19 vs control | FOXP4 | rs1886814 | Positive | Susceptibility | 0.307 | 1.14 | 0.0035 |
| Namkoong_rs1886814 | Japan COVID-19 Task Force: a nation-wide consortium to elucidate host genetics of COVID-19 pandemic in Japan | Severe COVID-19 vs control | FOXP4 | rs1886814 | Positive | Severe | 0.317 | 1.29 | 0.000091 |
| Namkoong_rs1886814 | Japan COVID-19 Task Force: a nation-wide consortium to elucidate host genetics of COVID-19 pandemic in Japan | Young COVID-19 vs control | FOXP4 | rs1886814 | Positive | Susceptibility | 0.314 | 1.17 | 0.0045 |
| Namkoong_rs1886814 | Japan COVID-19 Task Force: a nation-wide consortium to elucidate host genetics of COVID-19 pandemic in Japan | Young severe COVID-19 vs cntrl | FOXP4 | rs1886814 | Positive | Severe | 0.34 | 1.42 | 0.00012 |
| COVID-19 HGI_rs1886814 | Mapping the human genetic architecture of COVID-19 | Hospitalised vs Controls | FOXP4 | rs1886814 | Positive | Severe | 0.042 | 1.262 | 0.00000000111 |
| Horowitz_2_rs1886814 | Genome-wide analysis provides genetic evidence that ACE2 influences COVID-19 risk and yields risk scores associated with severe disease | COVID-19 severe vs not hospitalised | FOXP4 | rs1886814 | positive | Severe | None | None | 0.018 |
